I-SPY is showcasing three results pertaining to how I-SPY’s adaptive trial design can help better understand tumor biology, how to more strategically stratify treatments, and seek higher rates of pathologic complete response (pCR).

1. Abstract 520: Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL

Description: RCB was prognostic in all subtypes of breast cancer. Moreover, RCB index distribution between randomized treatments differed by randomized treatments, which suggests patterns are due to experimental treatment class and disease phenotype.

Session 1: Breast Cancer—Loc/Reg/Adj
Type: Poster Session
Time: Saturday June 2, 8:00—11:30 AM
Location: Hall A, Board 12

Session 2: Breast Cancer—Loc/Reg/Adj
Type: Poster Discussion Session
Time: Saturday June 2, 3:00—4:15 PM
Location: Hall D 

2. Abstract 12099: Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients

Description: Small sample size results suggest that the measurement of AKT kinase substrate phosphoproteins could be predictive of MK2206 clinical activity in both HER2+ and HER2- tumors regardless of HR status. 

Session: Tumor Biology
Type: Poster Session
Time: Monday, June 4, 2018, 1:15—4:45 PM
Location: Hall A, Board 212

3. Abstract 12103: Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial

Description: Small sample size results suggest that activation levels of the TIE2 receptor may be predictive of T efficacy in HER2+ patients and signaling activation downstream of TIE2. Such AKT-mTOR signaling may correlate with response in the HER2+ and TN populations. 

Session: Tumor Biology
Type: Poster Session
Time: Monday, June 4, 2018, 1:15—4:45 PM
Location: Hall A, Board 216